A temperature-dependent in silico model of the human ether-a-go-go-related (hERG) gene channel.

ABSTRACT:

Introduction

Current regulatory guidelines for assessing the risk of QT prolongation include in vitro assays assessing drug effects on the human ether-à-go-go-related (hERG; also known as Kv11.1) channel expressed in cell lines. These assays are typically conducted at room temperature to promote the ease and stability of recording hERG currents. However, the new Comprehensive in vitro Proarrhythmia Assay (CiPA) paradigm proposes to use an in silico model of the human ventricular myocyte to assess risk, requiring as input hERG channel pharmacology data obtained at physiological temperatures. To accommodate current industry safety pharmacology practices for measuring hERG channel activity, an in silico model of hERG channel that allows for the extrapolation of hERG assay data across

SUBMITTER: Li Z 

PROVIDER: S-EPMC5042861 | biostudies-literature | 2016 Sep-Oct

REPOSITORIES: biostudies-literature